AstraZeneca to buy Gracell Biotechnologies for USD 1.2 billion Ruchika Sharma27 Dec 2023 10:00 AM ISTCambridge: AstraZeneca has entered into a definitive agreement to acquire Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical...
Lower HDL-C, total cholesterol and apolipoprotein A-I levels encountered in multiple myeloma Medha Baranwal21 Dec 2023 11:30 PM ISTCyprus: A recent study published in Atherosclerosis Plus has reported a significant reduction in HDL-C, total cholesterol (TC), and apolipoprotein A-I...
Sarclisa plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone: Sanofi Ruchika Sharma11 Dec 2023 2:30 PM ISTParis: Sanofi has announced that the Phase 3 trial investigating Sarclisa (isatuximab) in combination with carfilzomib, lenalidomide and...
Sanofi multiple myeloma drug Sarclisa phase 3 trial meets primary endpoint of progression-free survival Ruchika Sharma10 Dec 2023 11:30 AM ISTParis: Sanofi has announced that the Phase 3 IMROZ trial evaluating the investigational use of Sarclisa (isatuximab) in combination with...
Pfizer Elrexfio gets European Commission approval for Multiple Myeloma Ruchika Sharma9 Dec 2023 12:00 PM ISTThe conditional marketing authorization for ELREXFIO is valid in all 27 EU member states as well as Iceland, Liechtenstein, and Norway.
Bristol Myers Squibb Abecma approved for use in earlier lines of therapy for patients with relapsed or refractory Multiple Myeloma in Japan Ruchika Sharma7 Dec 2023 4:30 PM ISTTokyo: Bristol-Myers Squibb K.K. has announced that the company has received manufacturing and marketing approval of the supplemental New Drug...
GSK declares positive results from phase III trial for Blenrep in relapsed/ refractory multiple myeloma Ruchika Sharma28 Nov 2023 12:30 PM ISTLondon: GSK plc has announced positive headline results from a planned interim efficacy analysis of the DREAMM-7 head-to-head phase III trial...
US FDA to delay decision on Bristol Myers-2seventy bio cancer therapy Ruchika Sharma21 Nov 2023 2:30 PM ISTThe therapy was originally co-developed by bluebird bio but following its spin-off in 2021 became part of 2seventy's portfolio.
EU medicines regulator recommends conditional marketing nod for Pfizer blood cancer therapy Ruchika Sharma15 Oct 2023 2:15 PM ISTNew York: The European Union medicines regulator has recommended a conditional marketing authorization for U.S. drugmaker Pfizer's therapy for a type...
AbbVie blood cancer combo therapy fails in late-stage study Ruchika Sharma2 Oct 2023 1:00 PM ISTUnited States: AbbVie has said a late-stage study of its experimental combination therapy to treat a form of blood cancer failed to meaningfully...
European Commission nod to reduced dosing frequency for Janssen Tecvayli Ruchika Sharma20 Aug 2023 11:30 AM ISTTeclistamab is an off-the-shelf (or ready to use) bispecific antibody.
Pfizer Elrexfio bags USFDA accelerated nod for multiple myeloma treatment Ruchika Sharma16 Aug 2023 11:41 AM ISTNew York: Pfizer Inc. has announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval to ELREXFIO (elranatamab-bcmm) for...
